ClinicalTrials.gg
RecruitingNCT06960928Updated May 18, 2026

Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19

A Phase 3 interventional study of Low-dose sirolimus and Placebo in Long COVID-19, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Icahn School of Medicine at Mount Sinai · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Post-Acute COVID-19 Syndrome by Icahn School of Medicine at Mount Sinai — 6 open to participants now, 7 under way, 1 of them phase 3. Post-Acute COVID-19 Syndrome · Icahn School of Medicine at Mount Sinai.

Planned enrollment
4th of 10
80 · median 45
Started
2025
the only one that year
Phase 3
Only one
of the 10
Registered
7th of 10
by date

Among the 10 studies in Post-Acute COVID-19 Syndrome by Icahn School of Medicine at Mount Sinai, this one is the 4th largest by planned enrollment, is the only one that started in 2025, is the only one in phase 3, and was the 7th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

6 of the 10 studies in Post-Acute COVID-19 Syndrome by Icahn School of Medicine at Mount Sinai are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Post-Acute COVID-19 Syndrome by Icahn School of Medicine at Mount Sinai, or all of them as a file.
02

Study summary

The study is conducted in New York, New York at The Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai.

This is an IND-exempt, off-label, multi-ascending, randomized, placebo-controlled clinical trial of sirolimus (also known as rapamycin) in adults with Long COVID. There are 2 arms: Sirolimus and Placebo.

This study aims to evaluate the efficacy of Sirolimus in adults with Long COVID. Efficacy will be evaluated by measuring patient-reported outcomes in response to Sirolimus.

03

Conditions studied

  • Long COVID-19

Keywords

  • Long COVID-19
  • Post-Acute Sequelae of COVID-19 (PASC)
  • Sirolimus
  • Rapamycin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form
  • Any sex, aged 18+
  • Must be able to attend all study visits located at 5 East 98th St, New York, NY
  • Diagnosed with:

    • Long COVID

      • Documented clinical history of confirmed or suspected acute SARS-CoV-2 infection a minimum of 6 months prior to contact with the study team
      • Formal diagnosis of Long COVID from a physician
      • At least a six-month history of one of the following symptoms following SARSCoV-2 infection:

        • headache, memory loss, insomnia, mood disturbance, chest pain, palpitations, shortness of breath, cough, muscle pains, joint pains, or GI upset
        • AND at least moderate fatigue (measured by Fatigue Severity Score)
        • AND at least moderate post-exertional malaise (PEM) (measured by DePaul PEM screener)
        • Participants who are willing and able to comply with all data collection, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
        • Baseline EQ-VAS ≤70; EQ-VAS before the index infection ≥80 (this information is collected before randomization as part of the baseline survey)

Exclusion criteria

Exclusion Criteria:

  • Pre-existing conditions including, but not limited to:

    • conditions such as Chronic EBV, Multiple Sclerosis, Hashimoto's Disease, etc. which would impact the immunological profiling analysis.
    • A pre-2020 diagnosis of another Post-Acute Infectious Syndrome such as Chronic Lyme disease, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, etc.
    • Documented history of vaccine injury
    • History of lung or liver transplant
    • Known hepatic or renal impairment
    • Weighing less than 40 kg
    • Or any other chronic condition that has the potential to impact on immunological profiling, at the discretion of the research physician
  • Current use of sirolimus
  • Taking a medication with known interactions to sirolimus:

    • Strong Inhibitors - clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir, such that dose reduction may be necessary
    • Strong CYP3A4 Inducers - carbamazepine, dexamethasone, ethosuximide, , griseofulvin, phenytoin, primidone, progesterone, rifabutin, rifampin, nafcillin, nelfinavir, nevirapine, oxcarbazepine, phenobarbital, phenylbutazone, rofecoxib (mild), St John's wort, sulfadimidine, sulfinpyrazone, troglitazone, and grapefruit, such that dose increase may be necessary.
    • Drugs that may increase concentration when given with sirolimus - Verapamil, such that dose reduction may be necessary
    • Other drugs that have the potential to increase sirolimus blood concentrations include (but are not limited to): fluconazole, clotrimazole, troleandomycin, nicardipine, cisapride, and metoclopramide
    • Concomitant use of angiotensin-converting enzyme (ACE) inhibitors may increase the risk of developing angioedema.
  • Febrile illness within the last 3 months of planned baseline evaluation
  • Treatment with another drug or other investigational intervention within 3 months of planned baseline evaluation
  • Prophylactic use of aspirin (325 mg daily) for cardiovascular indications will be permitted in participants. All other medications for chronic medical conditions should be initiated at least two months prior to enrollment.
  • Uncontrolled diabetes, unstable ischemic heart disease, underlying pulmonary disease, history of an immunodeficiency or receiving therapy; history of coagulopathy or medication condition requiring long-term anticoagulation; history of hepatic impairment; taking angiotensin-converting enzyme (ACE) inhibitors
  • Participants who are planning to be or are pregnant
  • Participants who are nursing
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Low-dose sirolimus

    Participants will follow the escalation scheme and receive sirolimus for up to 12 weeks.

    Drug: Low-dose sirolimus

  • Placebo comparator
    Placebo

    Participants will follow the escalation scheme and receive the placebo for up to 12 weeks.

    Drug: Placebo

Interventions

  • DrugSirolimusStudies of SirolimusSirolimus pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will take sirolimus, at home, for 12 weeks (3 months). * 1 pill once a week for 2 weeks (1mg) * 2 pills once a week for 2 weeks (2mg) * 4 pills once a week for 8 weeks (4mg)

    Also known as: rapamycin

  • DrugPlacebo

    Participants will take a matching placebo, at home, for 12 weeks (3 months). * 1 pill once a week for 2 weeks (0mg) * 2 pills once a week for 2 weeks (0mg) * 4 pills once a week for 8 weeks (0mg)

06

What researchers measure

Primary outcomes

  1. European Quality of Life-Visual Analogue Scale (EQ-VAS)

    The EQ VAS records the patient's self-rated health on a visual analogue scale where the endpoints are labelled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0), with higher scores indicating better health state. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement.

    Time frame: Baseline (Week 0) and Post-treatment (Week 12 and Week 24)

Secondary outcomes

  1. The EuroQol Five-Dimensional Health Questionnaire (EQ-5D-5L)

    The EQ-5D-5L is a validated, standardized, generic instrument that is a preference-based health- related quality of life questionnaire. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. Full scale from 5 to 25, with higher score indicating poorer health outcomes.

    Time frame: Baseline (Week 0) and Post-treatment (Week 12 and Week 24)

  2. Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29)

    The PROMIS-29 v2.0 profile assesses pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain. The values of all item responses are averaged to generate subscores for each dimension. From these subscores, a global physical health score and a global mental health score are generated. The scores are translated into T-scores according to a reference population with a mean of 50 and a standard deviation of 10.

    Time frame: Baseline (Week 0) and Post-treatment (Week 12 and Week 24)

  3. General Symptom Questionnaire (GSQ-30)

    The General Symptom Questionnaire-30 (GSQ-30) is a valid and reliable instrument to assess symptom burden among patients with acute and post-treatment. The GSQ-30 total score ranges from 0 to 120, with higher scores indicating a greater symptom burden.

    Time frame: Baseline (Week 0) and Post-treatment (Week 12 and Week 24)

  4. Patient Health Questionnaire (PHQ-9)

    The PHQ-9 is a series of questions assessing presence and severity of depression symptoms. It evaluates each of the DSM-IV depression criteria and scores the responses from 0 ("Not at all") to 3 ("Nearly every day"). PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively. Full scale from 0-27, with higher score indicating more severe symptoms.

    Time frame: Baseline (Week 0) and Post-treatment (Week 12 and Week 24)

  5. Generalized Anxiety Disorder (GAD-7)

    The GAD-7 is a 7-item scale developed and validated to identify generalized anxiety disorder and its severity. It assesses the frequency of 7 anxiety symptoms and scores the responses from 0 ("Not at all") to 3 ("Nearly every day"). Total scores of 5, 10, and 15 correspond to mild, moderate, and severe generalized anxiety disorder, respectively. Full scale from 0-21, with higher score indicating more symptoms.

    Time frame: Baseline (Week 0) and Post-treatment (Week 12 and Week 24)

  6. Neuro-QoL™ v2.0 Cognitive Function-Short Form

    The Neuro-QoL Cognitive Function v2.0 short form assesses perceived difficulties in cognitive abilities, including memory, attention, decision making, planning, organizing, calculating, remembering, and learning. The short form consists of 8 questions assessed on a 5-point Likert scale, resulting in a raw score range of 8 to 40. A raw score is then converted to a T-score using conversion tables. Scores 0.5 - 1.0 SD worse than the mean (T-score 40-45) = mild symptoms/impairment. Scores 1.0 - 2.0 SD worse than the mean (T-score 30-40) = moderate symptoms/impairment. Scores 2.0 SD or more worse than the mean (T-score below 30) = severe symptoms/impairment.

    Time frame: Baseline (Week 0) and Post-treatment (Week 12 and Week 24)

  7. Single-item Sleep Quality Scale (SQS)

    The SQS is a visual analog scale that instructs respondents to rate their overall quality of sleep over a 7-day recall period from 0 to 10. Scores of 0, 1, 4, 7, and 10 correspond to terrible, poor, fair, good, and excellent, respectively. Higher scores indicate better sleep quality.

    Time frame: Baseline (Week 0) and Post-treatment (Week 12 and Week 24)]

  8. Fatigue Severity Scale

    The Fatigue Severity Scale (FSS) uses a 7-point scale (1-7) to assess fatigue, with higher scores indicating greater severity, and a total score ranging from 9 to 63. Higher scores indicate more severe fatigue.

    Time frame: Baseline (Week 0) and Post-treatment (Week 12 and Week 24)

  9. Fatigue Visual Analogue Scale [F-VAS])

    The F-VAS consists of 18 items related to fatigue and energy in a visual analogue scale from 0 to 100. A higher score indicates more fatigue.

    Time frame: Baseline (Week 0) and Post-treatment (Week 12 and Week 24)

  10. DePaul Post-Exertional Malaise Questionnaire (DSQ)

    The DSQ is designed to evaluate 54 classic ME/CFS symptoms, including fatigue, post-exertional malaise, sleep, pain, neurological/cognitive impairments, and autonomic, neuroendocrine, and immune symptoms. Each symptom's frequency and intensity are rated on a 5-point scale (0-4). Frequency and severity scores are multiplied by 25, added together, and then divided by 2 to create a composite frequency/severity score for each symptom. These scores range from 0 to 100, with higher scores indicating a greater symptom burden.

    Time frame: Baseline (Week 0) and Post-treatment (Week 12 and Week 24)

  11. Composite Autonomic Symptom Score 31(COMPASS-31)

    The COMPASS-31 is a 31-question self-assessment instrument of autonomic symptoms and function that is up-to-date, broadly applicable, easy to administer in a short amount of time, and based on a scientific approach. The total score ranges from 0 to 100, with higher scores indicating greater autonomic dysfunction.

    Time frame: Baseline (Week 0) and Post-treatment (Week 12 and Week 24)

  12. Pain (P-VAS)

    Using a visual analogue scale, patients mark a point on a line representing a continuum from "no pain" to "worst pain," with scores ranging from 0 to 100, where higher scores indicate greater pain.

    Time frame: Baseline (Week 0) and Post-treatment (Week 12 and Week 24)]

  13. University of California-Los Angeles (UCLA) Loneliness Scale (3-item)

    The UCLA Loneliness (3-item) Scale scores range from 3 to 9, with higher scores indicating greater perceived loneliness.

    Time frame: Baseline (Week 0) and Post-treatment (Week 12 and Week 24)

  14. Adapted Berkman-Syme Social Network/Connection Index

    This is a self-report questionnaire used to assess social integration and isolation, focusing on marital status, frequency of contact, and participation in social activities, particularly relevant for older adults. Each item is scored on a scale from 1-4 where higher values reflect greater frequency (e.g., 4 = "5 or more times a week"). For each respondent, a sum score is calculated by adding the scores of all five items, yielding a possible score range of 5-25. Higher sum scores reflect higher levels of social connection and lower social isolation.

    Time frame: Baseline (Week 0) and Post-treatment (Week 12 and Week 24)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 7, 2025
StartActual
Apr 18, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
May 31, 2027
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06960928
Collaborators
PolyBio Research Foundation, The Anlyan Center
Responsible party
David Putrino (Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
May 7, 2025
Start date
Apr 18, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
May 18, 2026

Study contacts

David Putrino, PT, PhD
Contact
coreresearch@mountsinai.org
212-241-7658
Mackenzie Doerstling, MPH
Contact
coreresearch@mountsinai.org
212-241-7658
David Putrino, PT, PhD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion